Interchangeability: When Biosimilars Can Be Substituted Automatically

When you pick up a prescription for insulin or a biologic drug like Humira, you might get a biosimilar instead. But here’s the real question: Can your pharmacist swap it out without asking your doctor? That’s where interchangeability comes in. It’s not just a buzzword-it’s a legal and medical gatekeeper that decides whether you get a cheaper version without a second signature from your prescriber. And right now, only in the United States does this system actually work the way it’s supposed to.

What Makes a Biosimilar Interchangeable?

Not all biosimilars are created equal. A biosimilar is a biologic drug that’s highly similar to an already-approved biologic-called the reference product. Think of it like a copy of a complex machine, not a simple pill. These drugs come from living cells, so even tiny changes in manufacturing can affect how they work. That’s why the FDA doesn’t treat them like generic pills.

Generic drugs, like those for high blood pressure or cholesterol, are chemically identical to their brand-name counterparts. The Hatch-Waxman Act lets pharmacists swap them automatically. But biosimilars? They’re not identical. They’re similar. So to get the green light for automatic substitution, a biosimilar must earn an extra designation: interchangeable.

The FDA requires more than just proving similarity. To be labeled interchangeable, a manufacturer must show that switching back and forth between the reference product and the biosimilar doesn’t increase risk or reduce effectiveness. That means real-world testing: patients get the reference drug, then switch to the biosimilar, then switch back-sometimes multiple times. The data must prove no clinically meaningful differences in safety, immune response, or how the drug works in the body.

As of November 2023, the FDA has approved 41 biosimilars. Only 10 of them carry the interchangeable label. The first was Semglee, an insulin glargine product approved in July 2021. Then came Cyltezo, the first interchangeable biosimilar for adalimumab (Humira), approved in August 2023. These aren’t just new drugs-they’re game-changers for cost and access.

Why Does This Matter?

Biologics are expensive. Drugs like Humira, Enbrel, or insulin can cost $7,000 to $10,000 a year. Biosimilars, even without interchangeability, are typically 15-30% cheaper. But if your pharmacy can’t swap them automatically, many patients never even see the lower price. Insurance companies often don’t cover biosimilars unless they’re interchangeable. Pharmacists, too, are hesitant to switch without clear rules.

Interchangeability removes the friction. When a biosimilar is interchangeable, pharmacists can substitute it without calling the doctor-just like generics. This means fewer delays, fewer refills, and lower out-of-pocket costs. A 2023 JAMA Health Forum study found that states with automatic substitution laws had 18.7% higher biosimilar use for insulin. Semglee, the first interchangeable insulin, hit 17.3% market share in just six months. Non-interchangeable biosimilars? They barely cracked 10%.

But here’s the catch: interchangeability doesn’t mean better. All FDA-approved biosimilars-interchangeable or not-are just as safe and effective as the original. The difference isn’t in quality. It’s in the rules around substitution.

State Laws Make It a Patchwork

The federal government says, “If it’s interchangeable, you can swap it.” But states say, “Not so fast.”

Forty states, including Arizona, allow pharmacists to substitute interchangeable biosimilars without telling the prescriber. In Arizona, pharmacists must still notify the patient, record the product used, and send a note to the doctor within five days. Other states, like California, require the substitution to save the patient money. If the biosimilar isn’t cheaper, they can’t swap it.

Then there are the holdouts. Alabama, Indiana, South Carolina, and Washington require prescriber approval before any substitution-even if the biosimilar is FDA-approved as interchangeable. Washington, D.C., and five other states have similar restrictions.

This mess creates real problems. A community pharmacist in California told a Reddit thread: “My pharmacy system doesn’t know the difference between states. I have to manually check each prescription. I’m spending hours a week just on biosimilar rules.” A 2022 survey by the National Community Pharmacists Association found 67% of independent pharmacists were confused about state laws. That’s not just frustrating-it’s risky.

What Happens When You’re Switched Without Knowing?

Patient experiences vary. One user on the Psoriasis Foundation forum wrote: “I switched from Humira to Hyrimoz and saved $800 a month. Zero side effects.” Another wasn’t so lucky: “My pharmacy substituted Hadlima without telling me. I had a reaction. Turns out I was allergic to an excipient.”

The FDA says biosimilars don’t cause more side effects. But patients can react to inactive ingredients-the fillers, stabilizers, or preservatives added during manufacturing. These aren’t part of the active drug, but they can still trigger allergies. And if you’re not told what you’re getting, you can’t connect a reaction to the right product.

A 2022 survey by the National Psoriasis Foundation found 63% of patients were satisfied after switching. But 28% said they were never informed. That’s a communication gap. And it’s not just about trust-it’s about safety.

Global Differences: The U.S. Is Alone

The United States is the only country with an official interchangeability designation. In Europe, the EMA approves biosimilars but doesn’t allow automatic substitution. Pharmacists can’t swap them without the doctor’s okay. Canada has a hybrid system: Health Canada might call a biosimilar interchangeable, but provinces decide whether to allow substitution. Japan requires extra clinical data but doesn’t use the term “interchangeable” at all.

Why does the U.S. do it differently? Because we built a system that tries to balance speed, cost, and control. The BPCIA, passed in 2010, created this pathway to bring down prices for biologics. But other countries prioritized caution. They worry about long-term effects from switching. The U.S. says the data shows it’s safe. And so far, it’s holding up.

The Big Debate: Should All Biosimilars Be Interchangeable?

There’s a bill in Congress right now-the Biosimilar Red Tape Elimination Act (H.R. 9500). It proposes eliminating the switching studies entirely. That would make every FDA-approved biosimilar automatically interchangeable.

Supporters say it’s long overdue. The Association for Accessible Medicines says it’s essential to unlock savings in the $300 billion biologics market. They argue that if a biosimilar is safe enough to be approved, it’s safe enough to be swapped.

Opponents, including PhRMA, warn it could harm patients. They cite studies showing 20.3% higher discontinuation rates in psoriasis patients after non-medical switching. That means people stopped treatment because of side effects or loss of effectiveness.

The FDA’s stance? “All approved biosimilars are as safe and effective as the reference product.” Interchangeability is about logistics, not safety.

What Pharmacists Need to Know

If you’re a pharmacist, you’re on the front lines. You need to know:

• Is the biosimilar FDA-designated as interchangeable?
• What does your state law say about substitution?
• Did the prescriber write “Do Not Substitute” or use a DAW code?
• Are you documenting the product, manufacturer, and date?
• Are you notifying the patient?

The American Pharmacists Association has trained over 12,450 pharmacists through its Biosimilars Certificate Program. Still, a 2023 survey found pharmacists spend nearly 9 hours a year just learning the rules. That’s not time they can spend with patients.

The Future: More Biosimilars, More Complexity

By 2025, 70% of the top 20 biologic drugs will have biosimilar competitors. Insulin, Humira, Enbrel, and others are all under pressure. Interchangeable versions will keep coming. But the system is creaking under its own weight.

Insurance companies are pushing for automatic substitution. Some require it by contract. But state laws vary. Pharmacies use different software. Patients get confused. Doctors aren’t always informed.

The path forward? Better education. Clearer state laws. And maybe, eventually, federal alignment. For now, the U.S. system works-but only if everyone knows the rules.

What You Should Do

If you’re a patient:

• Ask your doctor: “Is my biologic eligible for a biosimilar?”
• Ask your pharmacist: “Am I getting an interchangeable biosimilar?”
• Check your prescription label. It should list the manufacturer.
• If you notice new side effects after a switch, tell your doctor-and ask if it could be the drug.

If you’re a prescriber:

• Use “Dispense as Written” if you want to prevent substitution.
• Know your state’s rules. They change.
• Talk to your patients. They’re likely saving money-but they deserve to know why.

Interchangeability isn’t magic. It’s a tool. And like any tool, it only works if you know how to use it.